why choose us

First received: March 13, 2023

Clinical Trial: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Tenosynovial Giant Cell Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor

Brief Summary: The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT).The main questions it aims to answer are:Whether the Pimicotinib(ABSK021) works well in patients with TGCT.Whether the Pimicotinib(ABSK021) is safe in patients with TGCT.Participants will be asked to complete the study procedures:Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24…

Read more